EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Ducournau, P. [1 ]
Latimer, N. [2 ]
Sabate, E. [1 ]
Walzer, S. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[2] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66575-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A471 / A472
页数：2
相关论文
共 50 条
  • [31] THE COST EFFECTIVENESS ANALYSIS OF CAPDX VERSUS FOLFOX-4 REGIMENS WITH OR WITHOUT BEVACIZUMAB IN THE FIRST LINE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN HONG KONG
    Lee, V. W.
    Cheng, F.
    Wan, K. P.
    Chik, J.
    Chan, D.
    Cheng, A.
    Wong, K. H.
    VALUE IN HEALTH, 2017, 20 (05) : A109 - A109
  • [32] Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US
    Aballea, Samuel
    Chancellor, Jeremy V. M.
    Raikou, Maria
    Drummond, Michael F.
    Weinstein, Milton C.
    Jourdan, Sophia
    Bridgewater, John
    CANCER, 2007, 109 (06) : 1082 - 1089
  • [33] Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis
    Bonistalli, L
    Bardelli, F
    Costantini, M
    Trallori, G
    d'Albasio, G
    Messori, A
    CANCER JOURNAL - FRANCE, 1998, 11 (01): : 39 - 47
  • [34] Capecitabine as adjuvant treatment for stage III colon cancer
    Twelves, C
    Wong, A
    Nowacki, MP
    Abt, M
    Burris, H
    Carrato, A
    Cassidy, J
    Cervantes, A
    Fagerberg, J
    Georgoulias, V
    Husseini, F
    Jodrell, D
    Koralewski, P
    Kröning, H
    Maroun, J
    Marschner, N
    McKendrick, J
    Pawlicki, M
    Rosso, R
    Schüller, J
    Seitz, JF
    Stabuc, B
    Tujakowski, J
    Van Hazel, G
    Zaluski, J
    Scheithauer, W
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26): : 2696 - 2704
  • [35] Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer
    Soni, Amy
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 219 - 226
  • [36] Is capecitabine a cost-effective adjuvant treatment of stage III colon cancer in Ontario?
    Orchard, M. C.
    Hoch, J.
    Alibhai, S. M. H.
    VALUE IN HEALTH, 2008, 11 (03) : A60 - A60
  • [37] Is capecitabine a cost-effective adjuvant treatment of stage III colon cancer in Ontario?
    Orchard, M. C.
    Hoch, J. S.
    Alibhai, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] ADJUVANT THERAPY FOR STAGE-III COLON-CANCER - ECONOMICS RETURNS TO RESEARCH AND COST-EFFECTIVENESS OF TREATMENT
    BROWN, ML
    NAYFIELD, SG
    SHIBLEY, LM
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) : 424 - 430
  • [39] FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer
    Grothey, A
    Sargent, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3311 - 3313
  • [40] LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
    Lou, Yun-Ting
    Chen, Chao-Wen
    Fan, Yun-Ching
    Chang, Wei-Chiao
    Lu, Chien-Yu
    Wu, I-Chen
    Hsu, Wen-Hung
    Huang, Ching-Wen
    Wang, Jaw-Yuan
    PLOS ONE, 2015, 10 (04):
12345